CVE:PDP Pediapharm (PDP) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free PDP Stock Alerts C$0.30 +0.01 (+1.69%) (As of 12/18/2018) Add Compare Share Share Today's RangeC$0.29▼C$0.3150-Day RangeC$0.30▼C$0.3052-Week RangeC$0.25▼C$0.49Volume26,000 shsAverage Volume100,369 shsMarket CapitalizationC$66.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Pediapharm alerts: Email Address Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Pediapharm Stock (CVE:PDP)Pediapharm Inc. operates as a specialty pharmaceutical company in Canada. It distributes prescription medicines that are used to treat pathological conditions, which primarily affect children from infancy to 18 years of age; and commercializes non-prescription products, such as non-prescription drugs and medical devices that fulfill unmet medical needs of children. The company was incorporated in 2003 and is headquartered in Verdun, Canada.Read More PDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PDP Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive PDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pediapharm and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:PDP CUSIPN/A CIKN/A Webwww.pedia-pharm.com Phone+1-514-7622626FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio30.00 P/E Growth150Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio186.87 Current Ratio1.12 Quick Ratio0.71 Sales & Book Value Annual SalesC$11.16 million Price / Sales5.95 Cash FlowC$0.01 per share Price / Cash Flow23.08 Book ValueC($0.01) per share Price / Book-23.08Miscellaneous Outstanding Shares221,194,000Free FloatN/AMarket CapC$66.36 million OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Sylvain Chretien (Age 54)Pres, CEO & Director Mr. Roland BoivinChief Financial OfficerMr. Richard LabelleVP of Sales & MarketingMr. Benoît Hébert (Age 50)VP of Bus. Devel. & Licensing Mr. Normand Chartrand (Age 59)Consultant Key CompetitorsBriaCell TherapeuticsTSE:BCTMicrobix BiosystemsTSE:MBXEmerald Health TherapeuticsCVE:EMHProMIS NeurosciencesTSE:PMNSmall PharmaCVE:DMTView All Competitors PDP Stock Analysis - Frequently Asked Questions How have PDP shares performed in 2024? Pediapharm's stock was trading at C$0.30 at the beginning of 2024. Since then, PDP stock has increased by 0.0% and is now trading at C$0.30. View the best growth stocks for 2024 here. Is Pediapharm a good dividend stock? Pediapharm (CVE:PDP) pays an annual dividend of C$0.14 per share and currently has a dividend yield of 0.00%. What other stocks do shareholders of Pediapharm own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pediapharm investors own include eMagin (EMAN), Eleven Biotherapeutics (EBIO), Coro Mining (COP), Champion Iron (CIA), Anavex Life Sciences (AVXL), AVEO Pharmaceuticals (AVEO), Asterias Biotherapeutics (AST) and Apellis Pharmaceuticals (APLS). How do I buy shares of Pediapharm? Shares of PDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:PDP) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pediapharm Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.